Overview Dividends

(CNMD) CONMED - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2074101013

Orthopedic, Endoscopic, Electrosurgical, Insufflation, Monitoring

Health Care Equipment
Market Cap in USD: 1,207m

IPO / Inception: 1987-07-23
Return 12m vs S&P 500: -50.8%

EPS (Earnings per Share)

EPS CAGR: 0.25%
EPS Trend: 40.5%

Last SUE: 0.23
Qual. Beats: 0

Revenue

Rev. CAGR: 5.75%
Rev. Trend: 86.3%

Last SUE: 0.74
Qual. Beats: 0

Dividends

Dividend Yield	1.50%
Yield on Cost 5y	0.57%
Yield CAGR 5y	0.00%
Payout Consistency	96.4%
Payout Ratio	19.7%

Risk via 5d forecast
Volatility	40.4%
Value at Risk 5%th	63.7%
Relative Tail Risk	-4.24%

Reward TTM
Sharpe Ratio	-1.13
Alpha	-56.39
CAGR/Max DD	-0.31

Character TTM
Hurst Exponent	0.558
Beta	0.924
Beta Downside	0.662

Drawdowns 3y
Max DD	70.69%
Mean DD	38.32%
Median DD	45.33%

Description: CNMD CONMED November 12, 2025

CONMED Corporation (NYSE:CNMD) is a U.S.-based medical-technology firm that designs, manufactures and sells a broad portfolio of surgical devices for orthopedic, general, endoscopic and patient-monitoring applications. Its orthopedic line-featuring products such as BioBrace, TruShot with Y-Knot, and Agro Knotless Suture Anchors-targets minimally invasive sports-medicine procedures, while its Hall brand delivers battery-powered bone-cutting tools for orthopedics, spine, cardiothoracic and oral/maxillofacial surgery. The company also offers general-surgery platforms (AirSeal insufflation, Buffalo Filter smoke removal), endoscopic gastroenterology tools, and cardiac monitoring accessories, distributing directly to hospitals, surgery centers and specialty distributors worldwide.

Key performance indicators from the most recent fiscal year show CONMED generated approximately $1.02 billion in revenue, with the orthopedic segment contributing roughly 45 % and posting an 8 % year-over-year growth rate. Operating margins hovered near 12 %, and the firm reported a 5-year compound annual revenue growth (CAGR) of 4 % despite a competitive market. Sector-wide drivers that underpin CONMED’s outlook include the U.S. aging demographic (projected to increase demand for joint-replacement and sports-medicine procedures by ~3 % annually), continued adoption of minimally invasive techniques that favor battery-powered, autoclavable instruments, and favorable Medicare reimbursement trends for outpatient orthopedic surgeries.

For a deeper, data-rich assessment of CONMED’s valuation dynamics and how its growth catalysts compare to peers, you may find the analytical tools on ValueRay worth exploring.

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (64.1m TTM) > 0 and > 6% of Revenue (6% = 80.8m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA -0.76pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 25.79% (prev 27.85%; Δ -2.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 167.7m > Net Income 64.1m (YES >=105%, WARN >=100%)

Net Debt (814.8m) to EBITDA (191.5m) ratio: 4.25 <= 3.0 (WARN <= 3.5)

Current Ratio 2.10 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (31.1m) change vs 12m ago -0.20% (target <= -2.0% for YES)

Gross Margin 54.22% (prev 55.65%; Δ -1.44pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 58.10% (prev 55.62%; Δ 2.48pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 3.63 (EBITDA TTM 191.5m / Interest Expense TTM 32.6m) >= 6 (WARN >= 3)

Altman Z'' 2.54

(A) 0.15 = (Total Current Assets 662.2m - Total Current Liabilities 314.7m) / Total Assets 2.32b

(B) 0.25 = Retained Earnings (Balance) 572.0m / Total Assets 2.32b

(D) 0.40 = Book Value of Equity 523.1m / Total Liabilities 1.31b

Total Rating: 2.54 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 62.21

1. Piotroski 4.0pt

2. FCF Yield 7.37%

3. FCF Margin 11.05%

4. Debt/Equity 0.85

5. Debt/Ebitda 4.25

6. ROIC - WACC (= -1.54)%

7. RoE 6.49%

8. Rev. Trend 86.25%

9. EPS Trend 40.53%

What is the price of CNMD shares?

As of December 21, 2025, the stock is trading at USD 39.95 with a total of 347,062 shares traded.
Over the past week, the price has changed by -2.16%, over one month by -1.38%, over three months by -20.12% and over the past year by -42.14%.

Is CNMD a buy, sell or hold?

CONMED has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold CNMD.

Strong Buy: 0
Buy: 2
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the CNMD price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	50.2	25.7%
Analysts Target Price	50.2	25.7%
ValueRay Target Price	31.4	-21.5%

CNMD Fundamental Data Overview December 21, 2025

Market Cap USD = 1.21b (1.21b USD * 1.0 USD.USD)
P/E Trailing = 19.0195
P/E Forward = 27.027
P/S = 0.8961
P/B = 1.2461
P/EG = 5.29
Beta = 0.98
Revenue TTM = 1.35b USD
EBIT TTM = 118.1m USD
EBITDA TTM = 191.5m USD
Long Term Debt = 853.0m USD (from longTermDebt, last quarter)
Short Term Debt = 746.0k USD (from shortTermDebt, last quarter)
Debt = 853.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 814.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.02b USD (1.21b + Debt 853.8m - CCE 38.9m)
Interest Coverage Ratio = 3.63 (Ebit TTM 118.1m / Interest Expense TTM 32.6m)
FCF Yield = 7.37% (FCF TTM 149.0m / Enterprise Value 2.02b)
FCF Margin = 11.05% (FCF TTM 149.0m / Revenue TTM 1.35b)
Net Margin = 4.75% (Net Income TTM 64.1m / Revenue TTM 1.35b)
Gross Margin = 54.22% ((Revenue TTM 1.35b - Cost of Revenue TTM 616.9m) / Revenue TTM)
Gross Margin QoQ = 49.16% (prev 55.01%)
Tobins Q-Ratio = 0.87 (Enterprise Value 2.02b / Total Assets 2.32b)
Interest Expense / Debt = 0.89% (Interest Expense 7.61m / Debt 853.8m)
Taxrate = 33.09% (1.41m / 4.27m)
NOPAT = 79.0m (EBIT 118.1m * (1 - 33.09%))
Current Ratio = 2.10 (Total Current Assets 662.2m / Total Current Liabilities 314.7m)
Debt / Equity = 0.85 (Debt 853.8m / totalStockholderEquity, last quarter 1.01b)
Debt / EBITDA = 4.25 (Net Debt 814.8m / EBITDA 191.5m)
Debt / FCF = 5.47 (Net Debt 814.8m / FCF TTM 149.0m)
Total Stockholder Equity = 987.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.76% (Net Income 64.1m / Total Assets 2.32b)
RoE = 6.49% (Net Income TTM 64.1m / Total Stockholder Equity 987.9m)
RoCE = 6.41% (EBIT 118.1m / Capital Employed (Equity 987.9m + L.T.Debt 853.0m))
RoIC = 4.22% (NOPAT 79.0m / Invested Capital 1.87b)
WACC = 5.77% (E(1.21b)/V(2.06b) * Re(9.42%) + D(853.8m)/V(2.06b) * Rd(0.89%) * (1-Tc(0.33)))
Discount Rate = 9.42% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.72%
[DCF Debug] Terminal Value 74.14% ; FCFE base≈155.8m ; Y1≈162.8m ; Y5≈188.4m
Fair Price DCF = 83.92 (DCF Value 2.60b / Shares Outstanding 31.0m; 5y FCF grow 4.74% → 3.0% )
EPS Correlation: 40.53 | EPS CAGR: 0.25% | SUE: 0.23 | # QB: 0
Revenue Correlation: 86.25 | Revenue CAGR: 5.75% | SUE: 0.74 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.95 | Chg30d=-0.068 | Revisions Net=-3 | Analysts=4
EPS next Year (2026-12-31): EPS=4.54 | Chg30d=-0.243 | Revisions Net=-3 | Growth EPS=+0.9% | Growth Revenue=+1.9%

Additional Sources for CNMD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle